(b).
Volume of whole blood | Volume of PRP injected | Number of injections during the study period | Study period | Pain scores evaluated in the study |
---|---|---|---|---|
200 ml | 2 ml | Single | 6 m | VAS RDQ |
9 ml | 2 ml | Single | 2-10 m | NRS ODI |
60 ml | 1.5-3 ml | Single | 24 w | VPS |
30 or 60 ml | 1.5 ml | Single, at one or multiple levels | 6 m | VAS ODI |
30 ml | 1-2 ml | Single, at one or multiple levels | 8 w | FRi, NRS, SF-36, and modified NASS |
200 ml | 2 ml | Single | 10 m | VAS RDQ |
Not mentioned | 1.5 ml | Single | 12 m | Improvement T2 nuclear signal intensity↑ |
Abbreviations: ACT: activation; BDI: Beck Depression Inventory; DPQ: Dallas Pain Questionnaire; FRI: functional rating index; L-PRP: leukocyte- and platelet-rich plasma; m: months; NRS: numerical rating scale; ODI: Oswestry Disability Index; P-PRP: leukocyte-poor PRP; PRP: platelet-rich plasma; RDQ: Roland-Morris Disability Questionnaire; SF: short form; SF-MPQ: short-form McGill Pain Questionnaire; vPS: verbal pain scale; w: weeks; VAS: visual analog scale; NASS: North American Spine Society.